NEW YORK and LONDON, December 5th, 2016 - Phase Ib cohorts demonstrate dose effect and additional support for once daily dosing- -PAS-Coversin pre-clinical …
Akari Therapeutics to Attend Upcoming Investor Conferences In November
NEW YORK and LONDON, November 11th, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today …
[Read more...] about Akari Therapeutics to Attend Upcoming Investor Conferences In November
Akari Therapeutics to Present Abstract on Potential Once Weekly PAS-Coversin at the 58th Annual Meeting of the American Society of Hematology
- Akari will host an analyst and investor symposium on Saturday, Dec 3 - NEW YORK and LONDON, November 3rd, 2016 Akari Therapeutics (NASDAQ: AKTX), an …
Akari Therapeutics Appoints New Members to its Board of Directors
NEW YORK and LONDON, October 14th, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the …
[Read more...] about Akari Therapeutics Appoints New Members to its Board of Directors
Akari Therapeutics Joins aHUS Alliance in Recognizing International aHUS Awareness Day
The 2nd annual aHUS Awareness Day will be marked on 24 September 2016. Updates from aHUS patient organizations and supporters from around the world will be …
